Detroit Free Press: ALS clinical trial could move to University of Michigan Hospital
An Atlanta-based clinical trial possibly could be making a move to the University of Michigan, reported the Detroit Free Press.
The trial is the first of its kind and aims to halt progress of the degenerative disease Amyotrophic Lateral Sclerosis — or ALS — more commonly referred to as Lou Gehrig's disease.
The procedure involves neural stem cells being injected directly into a patients spinal cord. Fifteen patients have undergone the surgery thus far.
Head of research and U-M Dr. Eva Feldman emphasized to the Free Press this trial still is strictly testing for safety, and cannot asses the success of treatment at this point.
The Food and Drug Administration continues to monitor the safety of the trial.